eli lilly and company

News

Eli Lilly, Mounjaro and cardiovascular disease

Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

PharmExec · 3h

Eli Lilly and Company’s Mounjaro Displayed Cardiovascular Protection in New Head-to-Head Trial

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 diabetes patients.

CNBC on MSN · 1d

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2 diabetes.

23hon MSN

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

2don MSN

Lilly set for strong quarter after Novo profit warning

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Eli Lilly’s weight loss drug most effective at preventing heart attacks and strokes: What new study means for Mounjaro users

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

What's Going On With Eli Lilly Stock On Tuesday?

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

PharmExec4d